A comprehensive portal site for Medical Innovation Support Office (MEDISO).Medical Innovation Support Office

Kensuke Suzuki

Nagashima Ohno & Tsunematsu
Partner, Attorney-at-law

Kensuke Suzuki is a partner at Nagashima Ohno & Tsunematsu. He represents both domestic and international clients, with a special focus on cross-border transactions, with respect to pharmaceutical, medical and healthcare business, M&A and corporate transactions, fund formation and management, and financial regulations. With expert knowledge of the Japanese medical, pharmaceutical, medical device, and other various healthcare-related regulations, he advises on a wide variety of business activities in the broad healthcare sector, such as regulatory compliance, data protection, mergers and acquisitions, alliances, business startups, financing, licensing and other commercial transactions. He was admitted to the Japan Bar in 2000 and worked as visiting attorney at Kirkland & Ellis （Chicago） from 2006 to 2007. He served as a special adviser to the Ministry of Health, Labour and Welfare from 2014 to 2015. He is fluent in Japanese and English.

Takahiro Mizumoto

Ant innovations Co., Ltd

Kyoto University Graduate School of Medicine, Master’s Program in Intellectual Property Management.
After passing the Japanese Patent Attorney Examination, gained venture investment experience in high-tech sectors including IT and healthcare at NIFS SMBC Capital (later split into Daiwa Corporate Investment and SMBC Venture Capital).
Subsequently joined Showa Shell Sekiyu, where he led the planning and development of multiple new services spanning payment solutions, retail electricity, and mobile app businesses. With the launch of the University of Tokyo Innovation Platform (UTokyo IPC), he joined the firm and founded 1stRound, a cross-university incubation program. He later spearheaded the establishment of an approximately JPY 25 billion open-innovation promotion fund and served as its Chief Investment Officer.
In November 2025, he founded Ant Innovations, a newly established venture capital firm and subsidiary of the private equity firm Ant Capital Partners, and assumed the role of Representative Director and Partner.

Hirokazu Yamaguchi

Kazuhiro Kanmuri

Inter-Professional Inc.

He engaged in pharmaceutical research and development for more than 25 years. He has gained experience in Japan and in the US development organization of Daiichi Sankyo Co., Ltd., Pfizer Inc., and CRO/consulting organizations, and has been deeply involved in strategic/regulaotry planning of clinical developmentincluding overseas organizations. His specialized fields are extensive, which include company clinical trials and investigator-initiated clinical trials, organization management, strategy development, and clinical trial operation/implementation, safety and pharmacovigillance, and he is active in the academic area of regulatory science. Currently, he engages in the consulting business as an expert in clinical development/organization and human resources development through the corporation that he established by himself and specialized CRO. In addition to being the incumbent, he concurrently served as a visiting lecturer of an academia organization, and he belongs to DIA Japan, an industry association of the pharmaceutical industry, and served as the Vice Program Committee Chair of the DIA Japan annual convention in 2018.

Yumi Kawata ,MD, PhD

Hedgehog MedTech, Inc.

She is Founder and CEO of Hedgehog MedTech, Inc, a start-up Digital Therapeutics (DTx) company. Previously, she was a manager with SoftBank Corp, where she evaluated new Healthcare & Life Science investment opportunities, managed relationships with strategic partners. Prior to SoftBank, she was a Government Relations specialist with Medley, Inc, where she built and maintained the relationships with Ministry of Health, Labour and Welfare and Academia. She launched researches and POCs, contributing to the spread of telemedicine in Japan. She also served as a technical officer for MHLW. she was involved in the management of researches on Rare and Intractable diseases and Infectious Diseases.